Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19114763 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL5969797 | 0.87 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL21766236 | 0.87 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL7154380 | 0.87 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL15912315 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTPLA2G1BATG4B | |
| SCHEMBL2464640 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL19115277 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TSHRHTTDHODHL3MBTL1 | |
| SCHEMBL5970025 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL5969969 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 | |
| SCHEMBL5969898 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TSHRDHODHL3MBTL1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885TSHR 4461/4885HTT 4394/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885TSHR 4461/4885HTT 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.